Evidence map›Paper›PMID 41791704›Full record

ArticleThe Journal of biological chemistry2026

Targeting the Golgi apparatus enhances PD-L1 blockade and synergizes with oxaliplatin to improve immunotherapy efficacy.

Haohuan Li, Chao Cui, Chenglu Sun, Ziyu Chen, Dengfeng Gao, Peng Yuan, Shibo Tian, Qin Zhong, Funeng Xu, Xiaoxia Liang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Haohuan LiCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China. Electronic address: lihaohuan@sicau.edu.cn.
Chao CuiCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Chenglu SunCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Ziyu ChenCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Dengfeng GaoCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Peng YuanCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Shibo TianCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Qin ZhongCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Funeng XuCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Xiaoxia LiangCollege of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan, China.
Long JinCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Keren LongCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Lu LuCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Juan DengCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Jiaxue CaoCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Xiaolan FanCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Fanli KongCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China.
Chengdong WangKey Laboratory of SFGA on Conservation Biology of Rare Animals, Giant Panda National Park, Chengdu, Sichuan, China.
Desheng LiKey Laboratory of SFGA on Conservation Biology of Rare Animals, Giant Panda National Park, Chengdu, Sichuan, China.
Zhiyong QianDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zhiyongqian@scu.edu.cn.
Mingzhou LiCollege of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China; College of Life Science, China West Normal University, Nanchong, Sichuan, China. Electronic address: mingzhou.li@sicau.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade targeting programmed death ligand-1 (PD-L1) has emerged as a cornerstone of cancer immunotherapy, yielding durable responses in subsets of patients across multiple malignancies. However, clinical outcomes remain limited because of incomplete blockade, low tumor immunogenicity, and poor targeting specificity. Here, we report the development of a chondroitin sulfate-modified liposomal formulation (OPCR-Lip) designed to achieve comprehensive PD-L1 blockade while reprogramming the tumor microenvironment to enhance immune activation. OPCR-Lip binds membrane-bound PD-L1, disrupts PD-L1 glycosylation, and inhibits exosomal PD-L1 secretion by damaging the Golgi apparatus, thereby mitigating immunosuppressive signaling. Codelivery of oxaliplatin further promotes immunogenic cell death, enhancing tumor immunogenicity and sustaining antitumor immunity in 4T1 breast tumor-bearing mice. The formulation's therapeutic precision was evaluated through circadian rhythm-based dosing, cross-species in vitro validation (canine and human breast cancer cells), and in vivo efficacy across melanoma and lung cancer models. Collectively, this study presents a promising therapeutic platform that augments PD-L1 blockade, broadens its clinical applicability, and improves treatment safety and effectiveness in solid tumors.

Indexed as

Antineoplastic AgentsB7-H1 AntigenGolgi ApparatusImmune Checkpoint InhibitorsImmunotherapyOxaliplatinAnimalsChondroitin SulfatesFemaleHumansLiposomesMiceMice, Inbred BALB CAntineoplastic AgentsB7-H1 AntigenCD274 protein, humanChondroitin SulfatesImmune Checkpoint InhibitorsLiposomesOxaliplatinexosomeglycosylationGolgi apparatus targetingimmunogenic cell deathPD-L1 blockade

Identifiers

PMID41791704
PMCPMC13053745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.